3092-LB: Effect of Obesity Management Medications on Physical Function: A Systematic Review and Meta-analysis
Diabetes · 05.06.2026 · 75 (Supplement_1)
DOI: 10.2337/db26-3092-lb ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Diabetes, erschienen am 05.06.2026. Verfasst von ALEXANDRA PEARY und 7 weiteren Autor:innen.
Abstract (Originalsprache)
Introduction and Objective: The beneficial effects of obesity management medications (OMMs) on weight loss are well recognized, but their impact on physical function remains incompletely understood. This systematic review and meta-analysis evaluated the effect of OMMs on physical function.
Methods
Eligible studies included randomized controlled trials of adults with overweight or obesity treated with an FDA-approved OMM (i.e., orlistat, phentermine/topiramate, naltrexone/bupropion, liraglutide, setmelanotide, semaglutide, tirzepatide). PubMed, Embase, and CINAHL databases were searched from inception through August 2025. Physical function outcomes included validated self-report or objective measures. Risk of bias was evaluated using the Cochrane Risk-of-Bias tool (version 2). Random-effects meta-analyses were conducted to estimate pooled mean differences (MD). Inter-study heterogeneity was assessed using the I2 statistic and Cochran’s Q test.
Results
Thirty studies with 25,068 participants were included. Relative to control, self-reported physical function improved with OMMs on both the Short-Form-36 (MD: 1.76 [95% CI: 1.20 to 2.32], I2 = 62.5%, p < 0.01) and Impact of Weight on Quality-of-Life (MD: 5.58, [95% CI: 4.24 to 6.92], I2 = 65.8%, p < 0.01) self-report measures. Three studies reported objective physical function, suggesting modest gains relative to control (Six-Minute Walk Test MD: 13.95, [95% CI: 5.84 to 22.07], I2 = 31.8%, p = 0.23).
Conclusion
OMMs improved patients’ perceived physical function. Current evidence is largely based on self-reported outcomes, and incorporating objective functional assessments into research is needed to further evaluate treatment effectiveness. Disclosure A. Peary: None. F. Montoya: None. N. Vaidya: None. M. Li: None. S.N. Lopez: None. C. Santos: None. J. Tong: None. A.M. Chao: Advisory Panel; Current; Eli Lilly and Company. Advisory Panel; Ended; Novo Nordisk. Advisory Panel; Current; Boehringer Ingelheim International GmbH. Advisory Panel; Ended; Roche Pharmaceuticals. Research Support; Current; Eli Lilly and Company. Funding National Institutes of Health (R01NR020197, R01NR021699, T32NR020315)
Zitieren
APA
PEARY, A., MONTOYA, F., VAIDYA, N., LI, M., LOPEZ, S. N., SANTOS, C., TONG, J., & CHAO, A. M. (2026). 3092-LB: Effect of Obesity Management Medications on Physical Function: A Systematic Review and Meta-analysis. Diabetes, 75(Supplement_1). https://doi.org/10.2337/db26-3092-lb
Vancouver
PEARY A, MONTOYA F, VAIDYA N, LI M, LOPEZ SN, SANTOS C, et al. 3092-LB: Effect of Obesity Management Medications on Physical Function: A Systematic Review and Meta-analysis. Diabetes. 2026;75(Supplement_1). doi:10.2337/db26-3092-lb
BibTeX
@article{PEARY2026,
author = {PEARY, ALEXANDRA and MONTOYA, FERNANDA and VAIDYA, NAINIKA and LI, MINGJIA and LOPEZ, SYDNEY N. and SANTOS, CAROLINA and TONG, JIAYI and CHAO, ARIANA M.},
title = {3092-LB: Effect of Obesity Management Medications on Physical Function: A Systematic Review and Meta-analysis},
journal = {Diabetes},
year = {2026},
volume = {75},
number = {Supplement_1},
doi = {10.2337/db26-3092-lb}
}
EUVIMED